Literature DB >> 3481318

Interaction between quinolones and caffeine.

A H Staib1, W Stille, G Dietlein, P M Shah, S Harder, S Mieke, C Beer.   

Abstract

The effects of multiple doses of ofloxacin 200 mg, ciprofloxacin 250 mg or enoxacin 400 mg (all twice daily) on the pharmacokinetic properties of single doses of caffeine (220 to 230 mg) were investigated in 12 healthy volunteers. Intraindividual comparisons showed that ciprofloxacin and enoxacin significantly inhibited the elimination of caffeine. Ofloxacin, however, did not affect any of the measured pharmacokinetic properties of caffeine. Thus, caffeine should be avoided in patients with liver disorders, cardiac arrhythmias, latent epilepsy or in intensive care while undergoing treatment with enoxacin or ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481318     DOI: 10.2165/00003495-198700341-00035

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Pharmacokinetics of ofloxacin and theophylline alone and in combination.

Authors:  J B Fourtillan; J Granier; B Saint-Salvi; J Salmon; A Surjus; D Tremblay; M Vincent Du Laurier; S Beck
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  [Gyrase inhibitors can delay caffeine elimination].

Authors:  A H Staib; S Harder; S Mieke; C Beer; W Stille; P M Shah; K Frech
Journal:  Dtsch Med Wochenschr       Date:  1986-09-26       Impact factor: 0.628

3.  Measurement of theophylline absorption from different regions of the gastro-intestinal tract using a remote controlled drug delivery device.

Authors:  A H Staib; D Loew; S Harder; E H Graul; R Pfab
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Quinolones and raised plasma concentrations of theophylline.

Authors:  F P Maesen; J P Teengs; C Baur; B I Davies
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

5.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

  5 in total
  10 in total

1.  In vivo and in vitro toxicodynamic analyses of new quinolone-and nonsteroidal anti-inflammatory drug-induced effects on the central nervous system.

Authors:  H Kita; H Matsuo; H Takanaga; J Kawakami; K Yamamoto; T Iga; M Naito; T Tsuruo; A Asanuma; K Yanagisawa; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.

Authors:  A Anadón; M R Martinez-Larrañaga; M C Fernandez; M J Diaz; P Bringas
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 4.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 5.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 6.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

7.  Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.

Authors:  G Mahr; F Sörgel; G R Granneman; M Kinzig; P Muth; K Patterson; U Fuhr; P Nickel; U Stephan
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 8.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

9.  Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.

Authors:  Min-Ho Park; Seok-Ho Shin; Jin-Ju Byeon; Gwan-Ho Lee; Byung-Yong Yu; Young G Shin
Journal:  Korean J Physiol Pharmacol       Date:  2016-12-21       Impact factor: 2.016

10.  Use of therapeutic caffeine in acute care postoperative and critical care settings: a scoping review.

Authors:  M Bright; V Raman; K B Laupland
Journal:  BMC Anesthesiol       Date:  2021-03-31       Impact factor: 2.217

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.